Daniel Albertson
No Rating Available
(Learn About Our Rating System)

Daniel Albertson, MD

Languages spoken: English

  • Dr. Albertson is an associate professor of pathology at the University of Utah School of Medicine and currently serves as the Division Chief for Anatomic Pathology and Molecular Oncology. He previously served as the Section Head for Surgical Pathology as well as the head of Genitourinary Pathology. He received his MD from the University of Nebraska and completed his residency in anatomic and clinical pathology at Creighton University, followed by a surgical pathology fellowship at the University of Utah. While at Creighton, Dr. Albertson served as the chief resident for two years and received the Hal Lankford Pathology Resident Award. He is a member of United States and Canadian Academy of Pathology and the College of American Pathologists. Dr. Albertson’s special research interests include genitourinary, gynecologic and solid tumor pathology.

    Specialties

    • Pathology, Anatomical

    Board Certification

    American Board of Pathology (Anatomic & Clinical)
    National Board of Medical Examiners

  • Dr. Albertson is an associate professor of pathology at the University of Utah School of Medicine and currently serves as the Division Chief for Anatomic Pathology and Molecular Oncology. He previously served as the Section Head for Surgical Pathology as well as the head of Genitourinary Pathology. He received his MD from the University of Nebraska and completed his residency in anatomic and clinical pathology at Creighton University, followed by a surgical pathology fellowship at the University of Utah. While at Creighton, Dr. Albertson served as the chief resident for two years and received the Hal Lankford Pathology Resident Award. He is a member of United States and Canadian Academy of Pathology and the College of American Pathologists. Dr. Albertson’s special research interests include genitourinary, gynecologic and solid tumor pathology.

    Board Certification and Academic Information

    Academic Departments Pathology -Primary
    Board Certification
    American Board of Pathology (Anatomic & Clinical)
    National Board of Medical Examiners

    Education history

    Fellowship Surgical Pathology - University of Utah Department of Pathology/ARUP Laboratories Fellow
    Creighton University Medical Center Chief Resident
    Residency Residency Program (Anatomic & Clinical Pathology) - Creighton University Medical Center, Department of Pathology Resident
    Medicine - University of Nebraska College of Medicine M.D.
    Undergraduate Summa Cum Lade - Xavier University, Natural Sciences B.S.

    Selected Publications

    Journal Article

    1. Luo MX, Lyle A, Bennett P, Albertson D, Sirohi D, Maughan BL, McMurtry V, Mahlow J (2024). Artificial intelligence chatbot vs pathology faculty and residents: Real-world clinical questions from a genitourinary treatment planning conference. Am J Clin Pathol. (Read full article)
    2. Ferrero A, Ghelichkhan E, Manoochehri H, Ho MM, Albertson DJ, Brintz BJ, Tasdizen T, Whitaker RT, Knudsen BS (2024). HistoEM: A Pathologist-Guided and Explainable Workflow Using Histogram Embedding for Gland Classification. Mod Pathol, 37(4), 100447. (Read full article)
    3. Mahlow J, Barry M, Albertson DJ, Jo YJ, Balatico M, Seasor T, Gebrael G, Kumar SA, Sayegh N, Tripathi N, Agarwal N, Swami U, Sirohi D (2024). Histologic patterns in prostatic adenocarcinoma are not predictive of mutations in the homologous recombination repair pathway. Hum Pathol, 144, 28-33. (Read full article)
    4. Wilcock D, Sirohi D, Albertson D, Cleary AS, Coleman JF, Jedrzkiewicz J, Mahlow J, Ruano AL, Gulbahce HE (2023). Clinicopathologic Features of Breast Carcinoma With 2018 American Society of Clinical Oncology/College of American Pathologists Fluorescence In Situ Hybridization Group 3 (Human Epidermal Growth Factor Receptor 2 Chromosome 17 Centromere Ratio <2.0 and Average Human Epidermal Growth Factor Receptor 2 Copy Number ≥6.0) Breast Cancers. Arch Pathol Lab Med. (Read full article)
    5. Wilcock DM, Moore KH, Rowe L, Mahlow J, Jedrzkiewicz J, Cleary AS, Lomo L, Ruano AL, Gering M, Bradshaw D, Maughan M, Tran P, Burlingame J, Davis R, Affolter K, Albertson DJ, Adelhardt P, Kim JT, Coleman JF, Deftereos G, Gulbahce EH, Sirohi D (2023). Quantitative Imaging Analysis Fluorescence In Situ Hybridization Validation for Clinical HER2 Testing in Breast Cancer. Arch Pathol Lab Med. (Read full article)
    6. Light N, Layeghifard M, Attery A, Subasri V, Zatzman M, Anderson ND, Hatkar R, Blay S, Chen D, Novokmet A, Fuligni F, Tran J, de Borja R, Agarwal H, Waldman L, Abegglen LM, Albertson D, Finlay JL, Hansford JR, Behjati S, Villani A, Gerstung M, Alexandrov LB, Somers GR, Schiffman JD, Rotter V, Malkin D, Shlien A (2023). Germline TP53 mutations undergo copy number gain years prior to tumor diagnosis. Nat Commun, 14(1), 77. (Read full article)
    7. Wilcock DM, McMurtry V, Coleman JF, Kim JT, Khalili P, Deftereos G, Albertson D, Gulbahce EH, Liu T, Sirohi D (2022). Histopathological Correlation of Chromosome 12 Polysomy by Fluorescence in Situ Hybridization in Adipocytic Neoplasms. Int J Surg Pathol, 30(7), 734-742. (Read full article)
    8. Sirohi D, Chipman J, Barry M, Albertson D, Mahlow J, Liu T, Raps E, Haaland B, Sayegh N, Li H, Rathi N, Sharma P, Agarwal N, Knudsen B (2022). Histologic Growth Patterns in Clear Cell Renal Cell Carcinoma Stratify Patients into Survival Risk Groups. Clin Genitourin Cancer, 20(3), e233-e243. (Read full article)
    9. Tward J, Lenz L, Flake DD II, Rajamani S, Yonover P, Olsson C, Kapoor DA, Mantz C, Liauw SL, Antic T, Fabrizio M, Salzstein D, Shore N, Albertson D, Henderson J, Lee SP, Gay HA, Michalski J, Hung A, Raben D, Garraway I, Lewis MS, Nguyen PL, Marshall DT, Brawer MK, Stone S, Cohen T (2021). The Clinical Cell-Cycle Risk (CCR) Score Is Associated With Metastasis After Radiation Therapy and Provides Guidance on When to Forgo Combined Androgen Deprivation Therapy With Dose-Escalated Radiation. Int J Radiat Oncol Biol Phys, 113(1), 66-76. (Read full article)
    10. Ward M, Albertson D, Furtado LV, Deftereos G (2020). PD-L1 Tumor Cell Expression in Upper Tract Urothelial Carcinomas is Associated With Higher Pathologic Stage. Appl Immunohistochem Mol Morphol, 30(1), 56-61. (Read full article)
    11. Gupta S, Albertson DJ, Parnell TJ, Butterfield A, Weston A, Pappas LM, Dalley B, OShea JM, Lowrance WT, Cairns BR, Schiffman JD, Sharma S (2018). Histone Deacetylase Inhibition Has Targeted Clinical Benefit in ARID1A-Mutated Advanced Urothelial Carcinoma. Mol Cancer Ther, 18(1), 185-195. (Read full article)
    12. Tward JD, Poppe MM, Hitchcock YJ, ONeil B, Albertson DJ, Shrieve DC (2018). Demographics, stage distribution, and relative roles of surgery and radiotherapy on survival of persons with primary prostate sarcomas. Cancer Med, 7(12), 6030-6039. (Read full article)
    13. Monument MJ, Grossmann AH, Baker CC, Randall RL, Liu T, Albertson DJ (2015). Molecular Confirmation of Ewing Sarcoma in an 85-Year-Old Woman. Int J Surg Pathol, 23(6), 500-4. (Read full article)
    14. Witt BL, Albertson DJ, Coppin MG, Horrocks CF, Post M, Gulbahce HE (2014). Use of in situ hybridization for HPV in head and neck tumors: experience from a national reference laboratory. Head Neck Pathol, 9(1), 60-4. (Read full article)
    15. Foulks JM, Carpenter KJ, Luo B, Xu Y, Senina A, Nix R, Chan A, Clifford A, Wilkes M, Vollmer D, Brenning B, Merx S, Lai S, McCullar MV, Ho KK, Albertson DJ, Call LT, Bearss JJ, Tripp S, Liu T, Stephens BJ, Mollard A, Warner SL, Bearss DJ, Kanner SB (2014). A small-molecule inhibitor of PIM kinases as a potential treatment for urothelial carcinomas. Neoplasia, 16(5), 403-12. (Read full article)